-
Mashup Score: 3Treatment of pulmonary arterial hypertension: recent progress and a look to the future - 8 month(s) ago
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic science discoveries, randomised controlled trials, studies of real-world data, and the development of clinical practice guidelines, considerable progress has been made in the treatment options and outcomes for patients with PAH, underscoring the importance of seamless translation of information from bench to bedside and, ultimately, to patients.
Source: www.thelancet.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Lung Story Short: A New Therapy for Pulmonary Arterial Hypertension | NEJM Resident 360 - 11 month(s) ago
Pulmonary arterial hypertension (PAH) involves the obliteration of the small arterioles of the pulmonary vasculature. PAH is categorized as World Health Organization (WHO) group 1 pulmonary hypertension, based on the presence of elevated pulmonary arterial pressures, normal pulmonary capillary wedge/left heart… | NEJM Resident 360
Source: mms.orgCategories: General Medicine News, Latest HeadlinesTweet-
From Pages to Practice: Lung Story Short: A New Therapy for #PulmonaryArterialHypertension. https://t.co/KHAUqa0tUz #MedEd #MedTwitter #PAH https://t.co/8mW4khqjl7
-
-
Mashup Score: 3Pulmonary arterial hypertension - European Lung Foundation - 12 month(s) ago
Pulmonary arterial hypertension (PAH) is a rare condition affecting about 15 to 50 people out of every million. It is caused by very high blood pressure in the arteries that lead from the heart to the lungs, known as the pulmonary arteries. This increase in blood pressure puts strain on the heart, and will eventually […]
Source: European Lung FoundationCategories: Latest Headlines, PulmonologyTweet-
On #WorldPHDay, the European Lung Foundation’s information hub on #pulmonaryarterialhypertension is a useful resource to share with patients. The resource is available in multiple languages. Read more: https://t.co/yXGOjvd6aa @EuropeanLung
-
-
Mashup Score: 2JCI Insight - Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension - 1 year(s) ago
Resource and Technical AdvanceIn-Press PreviewCardiologyPulmonology Open Access | 10.1172/jci.insight.163932 Rui-Sheng Wang,2 Christelle Guillermier,3 Christiane V.R. Hütter,4 William M. Oldham,1 Jörg Menche,5 Matthew L. Steinhauser,6 and Bradley A. Maron2 1Department of Medicine, Division of Pulmonary and Critical Medicine,…
Source: insight.jci.orgCategories: General Medicine News, Latest HeadlinesTweet-
Investigators capture a 'molecular snapshot' to illuminate the origins of #pulmonaryarterialhypertension @brighamwomens @JCI_Insight https://t.co/iXgQXC9W6b https://t.co/gE3zmQyUXT
-
-
Mashup Score: 0Caring for Patients With Pulmonary Arterial Hypertension (PAH) During the COVID-19 Pandemic - 1 year(s) ago
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. Pulmonary arterial hypertension is a rare, progressive disorder…
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. @ClevelandClinic @BayerPharma @BayerUS https://t.co/6ncNHzTMWF #pulmonaryarterialhypertension #PAH #raredisease
-
-
Mashup Score: 0
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high […]
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic, discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). @ClevelandClinic https://t.co/imNAz59Ak5 #raredisease #PAH #pulmonaryarterialhypertension
-
-
Mashup Score: 0Caring for Patients With Pulmonary Arterial Hypertension (PAH) During the COVID-19 Pandemic - 1 year(s) ago
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. Pulmonary arterial hypertension is a rare, progressive disorder…
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. @ClevelandClinic @BayerPharma @BayerUS https://t.co/6ncNHzTMWF #pulmonaryarterialhypertension #PAH #raredisease
-
-
Mashup Score: 0
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high […]
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic, discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). @ClevelandClinic https://t.co/imNAz59Ak5 #raredisease #PAH #pulmonaryarterialhypertension
-
-
Mashup Score: 1Caring for Patients With Pulmonary Arterial Hypertension (PAH) During the COVID-19 Pandemic - 1 year(s) ago
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. Pulmonary arterial hypertension is a rare, progressive disorder…
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic discusses caring for patients with pulmonary arterial hypertension (PAH) during the COVID-19 pandemic. @ClevelandClinic @BayerPharma @BayerUS https://t.co/6ncNHzTMWF #pulmonaryarterialhypertension #PAH #raredisease
-
-
Mashup Score: 0
Gustavo A. Heresi, MD, MS, Director of the Pulmonary Vascular and Chronic Thromboembolic Pulmonary Hypertension Program in the Department of Pulmonary and Critical Care Medicine in the Respiratory Institute at Cleveland Clinic discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). PAH is a rare, progressive disorder characterized by high […]
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Gustavo A. Heresi, MD, MS, at Cleveland Clinic, discusses the challenges of diagnosing and treating patients with pulmonary arterial hypertension (PAH). @ClevelandClinic https://t.co/imNAz59Ak5 #raredisease #PAH #pulmonaryarterialhypertension
-
Marc Humbert, @AlbertaPHdoc, and colleagues review recent progress and consider future directions for the treatment of #PulmonaryArterialHypertension https://t.co/OWWR9YYnvq #PulmonaryHypertension #PH #PAH https://t.co/gBQkW9cT3j